by Bioblast Editor | Dec 10, 2020 | Biosimilars updates
Merck receives a positive opinion from the EU’s CHMP for an extended indication set for Keytruda® (pembrolizumab). If approved, Keytruda® will also be indicated for metastatic microsatellite instability-high or mismatch repair deficient colorectal...
by Bioblast Editor | Sep 1, 2020 | Biosimilars updates
NeuClone Pharmaceuticals discloses it is working on a biosimilar referencing Keytruda® (pembrolizumab). The product is in the advanced stages of pre-clinical development and is being developed in partnership with the Serum Institute of India.
by Bioblast Editor | Aug 24, 2020 | Biosimilars updates
Merck announces Keytruda® (pembrolizumab) has received two additional approvals from the Japanese Pharmaceuticals and Medical Devices Agency: new indication for the treatment of patients whose tumours are PD-L1-positive, and have radically unresectable, advanced or...
by Bioblast Editor | Aug 19, 2020 | Biosimilars updates
Merck announces the results of Ph III trials of Keytruda® (pembrolizumab) in combination with chemotherapy for first-line treatment of patients with locally advanced or metastatic esophageal cancer. Merck reported that Keytruda® met the primary and secondary endpoints...
by Bioblast Editor | Jun 29, 2020 | Biosimilars updates
Merck announces the FDA has approved Keytruda® (pembrolizumab) for first-line treatment of patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.
